Adage Capital Partners’s IGM Biosciences IGMS Stock Holding History

Adage Capital Partners’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-400,000	Closed	-$3.32M	–	915
2023 Q4	$3.32M	Buy	+400,000	New	+$2.32M	0.01%	717

Other funds holding IGMS

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners's IGMS Position: Q1 2024 in Review

Adage Capital Partners sold out of IGM Biosciences (IGMS) in Q1 2024, closing a stake of 400,000 shares — an estimated $3.32M sold.

Adage Capital Partners first reported a position in IGMS in Q4 2023 and held it in 1 quarter. The position peaked at $3.32M in Q4 2023. 87 funds tracked by Wall St. Rank hold IGMS as of Q1 2024.

Adage Capital Partners reported no remaining IGM Biosciences position as of Q1 2024 after selling out during the quarter.
Adage Capital Partners sold 400,000 IGM Biosciences shares in Q1 2024, an estimated $3.32M.
Adage Capital Partners first reported a position in IGM Biosciences in Q4 2023 and held it in 1 quarter.
Adage Capital Partners's IGM Biosciences position peaked at $3.32M in Q4 2023.
87 funds tracked by Wall St. Rank held IGM Biosciences as of Q1 2024.

Based on Adage Capital Partners's 13F filing for Q1 2024, filed 15 May 2024.